<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="./css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body>

    <div class="main_page5 fixedHeight">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook mb-0"><strong>Chari et al. Optum’s EHR database, US Real-world study:</strong> <br> a retrospective, comparative efficacy analysis of PI-Rd triplets used in routine care in the US<sup class="GothamLight">1</sup></h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box -->
            <div class="page5_middle_box page8_middle_box bigLineHight mb-3">
                <div class="page8_middle_left">
                    <h4 class="txt_orange GothamBook mt-1 mb-4">STUDY <strong class="GothamBold">DESIGN:</strong></h4>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2 fs-14"><img class="mt-2 me-2" src="img/li_2.svg" alt=""> <span>A retrospective, comparative effectiveness <br> analysis in a representative cohort (Optum’s <br> EHR database) of patients with RRMM treated <br> in routine care with IRd, KRd, or VRd in second <br> line or later in the United States routine care<sup>1</sup></span></p>
                </div>
                <div class="page8_middle_right fs-14">
                    <h4 class="txt_orange GothamBook mt-1 mb-4">STUDY <strong class="GothamBold">ENDPOINTS:</strong></h4>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2"><img class="mt-2 me-2" src="img/li_2.svg" alt=""> <span>Time to next treatment (TTNT): a surrogate measure for PFS in Real-world analyses, defined as the time from the start of the index regimen to initiation of subsequent lines of therapy or death, whichever occurred earlier<sup>1</sup></p>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2"><img class="mt-2 me-2" src="img/li_2.svg" alt=""> <span>Duration of therapy (DOT): defined as time from initiation of the first drug in the index regimen to discontinuation of the last drug in the regimen plus a run-out period or death, whichever occurred earlier<sup>1</sup></p>
                </div>
            </div>
            <div class="page5_middle_box page8_middle_box_p mb-1 smlLineHight">
                <p class="GothamBook dark_secondary fs-11 m-0 p-0"><span class="fs-11">Study limitations:</span> Real-world analyses are often nonrandomised, observational, retrospective studies that may have unobserved treatment <br>
                    selection biases as well as other limitations that should be considered when comparing results with clinical trials. Outcomes should be <br>
                    interpreted with caution due to small sample size, limited follow-up, and limited maturity of data. The lack of head-to-head trials of PI-Rd <br>
                    triplet regimens has led to challenges in comparisons of treatment effects across trials.<sup>1</sup></p>
            </div>
        <!--  -->
            <div class="page5_middle_box pt-4 mt-2 mb-4">
                <div class="page5_btns_sm">
                    <a href="../page12/index.html" class="text-uppercase"><p class="mb-0 position-relative">TTNT RESULTS</p></a>
                    <a href="../page32/index.html" class="text-uppercase"><p class="mb-0 position-relative">SAFETY</p></a>
                    <a href="../page13/index.html" class="text-uppercase"><p class="mb-0 position-relative">PATIENT BASELINE CHARACTERISTICS</p></a>
                </div>
            </div>

            <div class="page5_middle_box page5_p_sm w-100 pt-1 mb-4">
                <p class="GothamLight">DOT = duration of therapy; EHR = electronic health record; KRd = carfilzomib + Rd; IRd = Ixazomib (NINLARO) + Rd; PI = proteasome inhibitor; PFS = progression-free survival; Rd = REVLIMID® (lenalidomide) + <br>
                    dexamethasone; RRMM = relapsed/refractory multiple myeloma; TTNT = time to next treatment; US = United States; VRd = bortezomib + REVLIMID® (lenalidomide) + dexamethasone</p>
            </div>


            <div class="footer_page5">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul>
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page14/index.html" class="text-uppercase">ref</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>